Prime Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prime Medicine (PRME).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

2S.Buy

9Buy

2Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$10Upside to Avg. PT+115.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$7
Aug 25, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$7
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$9
Aug 10, 2026	HC Wainwright & Co.	Arthur He	Maintained	Buy	$8
Jun 29, 2026	HC Wainwright & Co.	Arthur He	Upgrade	Neutral→Buy	$8
Mar 12, 2026	Oppenheimer	Kostas Biliouris	Initiate	Outperform	$11
Dec 23, 2025	LifeSci Capital	—	Initiate	Outperform	$6
Nov 11, 2025	Citigroup	Samantha Semenkow	PT Cut	Neutral	$5→$4
Nov 10, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$10→$9
Aug 12, 2025	Citigroup	Samantha Semenkow	PT Raise	Neutral	$2→$4
Aug 8, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$12→$10
May 27, 2025	Citigroup	Samantha Semenkow	Downgrade	Buy→Neutral	$10→$2
May 20, 2025	JMP Securities	Silvan Tuerkcan	PT Cut	Market Outperform	$10→$6
May 20, 2025	JP Morgan	Eric Joseph	Downgrade	Overweight→Neutral	—
May 20, 2025	HC Wainwright & Co.	Arthur He	Downgrade	Buy→Neutral	—
May 19, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$16→$12
Mar 20, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$15→$16
Mar 19, 2025	HC Wainwright & Co.	Arthur He	Maintained	Buy	$10
Mar 4, 2025	Citizens Capital Markets	Silvan Tuerkcan	Maintained	Market Outperform	$10
Mar 3, 2025	HC Wainwright & Co.	Arthur He	Maintained	Buy	$10

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.

Benzinga Newsdesk

This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgraded Warner Bros Discovery Inc with price targets.

Avi Kapoor

PRO
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.

Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6

LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.

Benzinga Newsdesk

Prime Medicine Inc

Prime Medicine Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

PRO
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

PRO
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

PRO
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

PRO
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6

People Also Watch

People Also Watch

Prime Medicine Inc

Prime Medicine Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

PROHC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

PROHC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

PROOppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

PROLifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6

People Also Watch

People Also Watch

PRO
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

PRO
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

PRO
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

PRO
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

PRO
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6